Sanofi, Transgene begin construction of bioproduction platform in Lyon, France
French pharmaceutical firm Sanofi along with its partner Transgene has announced the start of construction of a new manufacturing platform designed to produce viral vectors such as MUC1, a drug developed by Transgene that targets cancer immunotherapy, TG4010.
The new production unit being built on the Genzyme Polyclonals site in Lyon, France, will cost EUR10m over two years, with each company financing half the cost.
The new unit will be dedicated to production of viral vectors through a broad range of technologies including mammalian cell culture up to 1m3 using single use bioreactors, combining the excellence of Genzyme,
The deal will see Transgene get Sanofi’s
Transgene chairman and chief executive officer Philippe Archinard said, «Our decision to invest now reflects the increasing confidence in our programs, including our cancer immunotherapy candidate, TG4010, for which we recently announced topline preliminary data from a clinical study in
Through the Genzyme Polyclonals site for the manufacturing and the CEPIA (Commercial & External Partnership Industrial Affairs) organisation for all commercial aspects, Sanofi will act as Transgene’s Contract Manufacturing Organisation (CMO) and Transgene will be the preferred customer of the platform through 2028.
After completion, the production unit will be Sanofi’s exclusive property that will produce a new breakthrough class of APIs (Viral vectors).
Image: Sanofi’s corporate headquarters located at 54 rue La Boetie in Paris, France. Photo: courtesy of Sanofi